TICKERNERD
Menu
INFUINFUHealthcare · Medical Devices

INFU Stock Forecast: InfuSystem Holdings, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$12
+0.25% on the day

The 3 Wall Street analysts covering InfuSystem Holdings, Inc. hold a median 12-month price target of $18 — +44.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$242.0M
Ticker Nerd rank
100 / 100
Median analyst target
$18
Analysts covering
3
Revenue$36.9M+2.6% y/y
Operating income$4.2M
Net income$3.2M
Free cash flow$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
−2.5%
YTD
+35.5%
1Y
+19.9%
From 52W high
−2.7%
From 52W low
+63.7%
$7
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INFU stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores InfuSystem Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
100 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
98
Quality
98
Accruals
95
Momentum
89
Value
73
Revisions
72
Size
65
Growth
59
Volatility
46

Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.

Volatility (46): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INFU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INFU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14$16$18Oct 25Jan 26Apr 26Jul 26INFUHigh $18Median $18Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $15Median $18High $18

The green dot is the last close — the median target sits +44.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026B. Riley SecuritiesReiteratesBuy—
25 Feb 2026Roth CapitalReiteratesBuy—
5 Nov 2025Roth CapitalReiteratesBuy—
22 July 2025Roth CapitalInitiatesBuy—
26 Sept 2024B. Riley SecuritiesInitiatesBuy—
26 Apr 2021Northland Capital MarketsInitiatesOutperform—
31 Aug 2020Craig-HallumInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INFU appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INFU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, InfuSystem Holdings, Inc. returned +19.9% against +17.5% for the S&P 500, dividends included.

INFU vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Oct 25Jan 26Apr 26Jul 26INFUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INFU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.4%
Analysts raising
1
Analysts cutting
2
Fundamentals

InfuSystem Holdings, Inc. (INFU) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.4×

Cheaper than 25% of US stocks

Price / sales
1.7×

Cheaper than 57% of US stocks

Price / book
4.1×

Cheaper than 25% of US stocks

EV / EBITDA
11.0×

Cheaper than 35% of US stocks

Growth & margins
Revenue growth (YoY)
2.6%

Higher than 33% of US stocks

Earnings growth (YoY)
24.3%

Higher than 62% of US stocks

Gross margin
58.0%

Higher than 71% of US stocks

Operating margin
11.2%

Higher than 66% of US stocks

Net margin
6.0%

Higher than 62% of US stocks

Returns & dividend
Return on equity
15.0%

Higher than 74% of US stocks

Return on assets
7.1%

Higher than 85% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

InfuSystem Holdings, Inc. (INFU) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • InfuSystem Holdings, Inc. has a market value of $242.0M and an enterprise value of $265.6M.

  • Revenue in the twelve months to 30 June 2026: $143.3M. The latest quarter grew 2.6% year on year.

  • Net income over the same four quarters: $8.5M, a 6.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.41.

  • Free cash flow in the twelve months to 30 June 2026: $12.6M.

  • InfuSystem Holdings, Inc. spent $9.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 19.9M.

  • Trailing P/E: 30.4×; forward P/E: 23.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • InfuSystem Holdings, Inc. employs 461 people — $311K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

INFU vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INFUInfuSystem Holdings, Inc.$242.0M
100
RXSTRxSight, Inc.$249.2M
51
STIMNeuronetics, Inc.$230.9M
64
ELMDElectromed, Inc.$227.3M
94
LABStandard BioTools, Inc.$269.1M
35
TLSITriSalus Life Sciences, Inc.$279.0M
34
TMCITreace Medical Concepts, Inc.$287.4M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own InfuSystem Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INFU news & analysis

InfuSystems: More Upside Ahead

Seeking Alpha · 27 Aug 2026positive

InfuSystems reported a 24% FY25 adjusted EBITDA increase, driven by a profit-focused strategy that maintained strong margins despite GE contract restructuring. Wound Care revenue rose 154% on partnerships and favorable reimbursement, Oncology achieved record volumes, and the company kept a conservative balance sheet with net debt at 0.61x EBITDA, $55.2M liquidity, and share buybacks reducing share count by 5% in H1.

Why it matters — A watcher would care because the report highlights sustained profitability, strong revenue growth in key segments, and a conservative financial position amid contract restructuring.

The London Company Large Cap Vs. Russell 1000 Q2 2026 Portfolio Review

Seeking Alpha · 5 Aug 2026neutral

The London Company's Large Cap portfolio returned 10.9% (10.7% net) in Q2 2026 versus a 15.1% gain in the Russell 1000 Index. The review noted ENTG as a top contributor on improved fab utilization and AI-driven semiconductor demand, while RSG declined despite a solid quarter due to softer Environmental Solutions results and weak construction-related volumes.

Why it matters — The review does not mention InfuSystem Holdings, so a INFU watcher gains no direct company insight from this item.

Diamond Hill Small Cap Fund Q2 2026 Portfolio Activity

Seeking Alpha · 5 Aug 2026neutral

Diamond Hill Small Cap Fund reported its Q2 2026 portfolio activity, noting Astrana Health's outperformance tied to its Medicare coding practices, a decline in Magnolia Oil & Gas shares following the US-Iran war-ending agreement to reopen the Strait of Hormuz, and the initiation of a new position in Insteel Industries, a steel wire reinforcing products manufacturer.

Why it matters — The report's Q2 2026 portfolio activity contains no mention of InfuSystem Holdings, so it offers no direct insight relevant to INFU watchers.

InfuSystem Holdings, Inc. (INFU) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

Seeking Alpha published the transcript of InfuSystem Holdings, Inc.'s Q2 2026 earnings call. The item consists of the transcript's headline and source, with no details on the actual results discussed.

Why it matters — An INFU watcher would care because the earnings call transcript is the record of management's commentary on the company's second-quarter 2026 performance.

InfuSystems Holdings, Inc. (INFU) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 4 Aug 2026positive

InfuSystems Holdings reported Q2 earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.12 and improving from $0.12 per share in the same quarter last year. Revenues also surpassed estimates.

Why it matters — The earnings beat marks an improvement over the prior-year period and exceeded analyst expectations, signaling stronger-than-expected quarterly performance for INFU.

FAQ

Frequently asked questions about INFU stock

What is the INFU stock price forecast for 2026-2027?

The 3 Wall Street analysts covering InfuSystem Holdings, Inc. have a median 12-month price target of $18, with estimates ranging from $15 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INFU stock a buy right now?

Of the 3 analysts covering InfuSystem Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InfuSystem Holdings, Inc. 100 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INFU?

As at 12 Sept 2026, InfuSystem Holdings, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).

Will INFU stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +44.0% from the last close, and Ticker Nerd's factor model ranks InfuSystem Holdings, Inc. 100 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INFU stock forecast for 2030?

No analyst covering InfuSystem Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INFU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $18 over the next 12 months.

How has INFU stock performed over the past year?

InfuSystem Holdings, Inc. returned +19.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InfuSystem Holdings, Inc. do?

InfuSystem Holdings, Inc. is a healthcare services company focused on infusion pump management and related support for hospitals, oncology practices, surgery centers, and other alternate-site care providers.

What is the latest news on INFU?

The most recent item we track (Seeking Alpha, 27 Aug 2026): "InfuSystems: More Upside Ahead". InfuSystems reported a 24% FY25 adjusted EBITDA increase, driven by a profit-focused strategy that maintained strong margins despite GE contract restructuring. Wound Care revenue rose 154% on partnerships and favorable reimbursement, Oncology achieved record volumes, and the company kept a conservative balance sheet with net debt at 0.61x EBITDA, $55.2M liquidity, and share buybacks reducing share count by 5% in H1.

Company

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is a healthcare services company focused on infusion pump management and related support for hospitals, oncology practices, surgery centers, and other alternate-site care providers. InfuSystem provides electronic ambulatory infusion pumps, disposable supply kits, and associated clinical, biomedical, logistics, billing, maintenance, and repair services that support outpatient therapy workflows. Its offerings serve oncology clinics, home infusion providers, and other care settings where durable medical equipment and ongoing treatment coordination are required. The company operates through two core segments, Patient Services and Device Solutions, combining equipment access with technical servicing and patient support. Headquartered in Rochester Hills, Michigan, InfuSystem plays a specialized role in the medical device services market by helping healthcare providers manage infusion therapy across clinic-to-home care environments in the United States and Canada.

CEO Ms. Carrie A. Lachance B.S.N., M.B.A., R.N. · 461 employees · United States · https://www.infusystem.com